Overview
Indications
Methylene blue injection is indicated for the treatment of pediatric and adult patients with acquired methemoglobinemia.
Boxed Warning
FDA Black Box Warning
Warnings and Precautions (5.1) Drug Interactions (7.1) [seeand]. Methylene blue injection may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. Avoid concomitant use of Methylene blue injection with selective serotonin reuptake inhibitors (SSR
Contraindications
When this intervention should not be used
Methylene blue is contraindicated in the following conditions: Warnings and Precautions (5.2) [see] Severe hypersensitivity reactions to methylene blue or any other thiazine dye. Warnings and Precautions (5.3, 5.4) [see] Patients with glucose-6-phosphate dehydrogenase deficiency (G6PD) due to the ri
Indications & Related Conditions
Conditions associated via SNOMED clinical relationships
Administration & Protocol
Dosing, route, and treatment protocol
Detailed dosage and administration information is available in the full FDA drug label.
View full prescribing information on DailyMedMonitoring & Follow-Up
Biomarkers relevant to this intervention via related conditions
No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.
Clinical Trials
15 trials linked to this intervention
Recent Trials
VALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 (HSV-2) Seropositive Subjects. VALTREX® Tablet is a Trademark of GlaxoSmithKline Group of Companies.
A Study of Valacyclovir to Suppress HSV and HIV Shedding in Coinfected Persons
A Randomized Controlled Trial of Acyclovir Among HIV and HSV-2 Co-Infected Women, Chiang Rai, Thailand
Asymptomatic Bacterial Vaginosis and Herpes Simplex Virus Type 2 (BV/HSV-2) Shedding Study
The Natural History of Severe Viral Infections and Characterization of Immune Defects in Patients Without Known Immunocompromise
Research Evidence
Published studies and systematic reviews
Research data from MEDLINE/PubMed
Benefits & Expected Outcomes
Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.
Risks & Side Effects
Adverse reaction and safety data for this drug is sourced from the FDA-approved label.
View adverse reactions & drug interactions on DailyMedRelated Symptoms
Symptoms associated with conditions this intervention addresses
No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.
Alternatives & Comparisons
Alternative treatments, comparison data, and clinical decision support are pending physician authorship.
This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.
Do not start, stop, or change any treatment without consulting your healthcare provider.
Quick Facts
- Type
- Substance / Medication
- Fully Specified Name
- Methylthioninium chloride (substance)
- SNOMED CT
- 6725000
- UMLS CUI
- C0025746
- RxNorm CUI
- 6878
- Labeler
- Hikma Pharmaceuticals USA Inc.
Clinical Data
This intervention maps to 4 entities in the Ltrl knowledge graph.
Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.